U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07206498) titled 'A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC' on Sept. 19.
Brief Summary: This is a Phase I/II, Open Label Study of WSD0922-FU in Combination with Osimertinib for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose disease has progressed with third-generation EGFR-TKI with C797S mutation or is newly diagnosed with CNS metastasis with EGFR Del19 or L858R mutation
Study Start Date: Oct. 15
Study Type: INTERVENTIONAL
Condition:
Non Small Cell Lung Cancer (NSCLC)
Intervention:
DRUG: Osimertinib (Tagrisso(R))
Drug: Osimertinib Procedure: Biospecimen Collection - bl...